Article
MET Amplification a Viable Screen for NSCLC, Study Claims
A study published in Clinical Cancer Research found that 33% of lung cancer biopsies evaluated had a gain of function amplification in the MET receptor tyrosine kinase.
MET
A third of non-small-cell lung cancers (NSCLCs) show low- to high-level amplification of the gene, according to a German study, with no significant difference in frequency across different types of cancer and genetic backgrounds.
MET
Hans-Ulrich Schildhaus, from University Hospital Göttingen, and colleagues explain that alterations in the expression levels of the MET receptor tyrosine kinase, a potential therapeutic target in lung cancer, can be caused by various mechanisms, of which gene amplification is one.
MET
Highlighting the “controversial” nature of amplification in NSCLC, they used fluorescence in situ hybridisation to assess its prevalence in 693 treatment-naive NSCLC patients, of whom 519 had adenocarcinomas and 174 had squamous cell carcinomas.
MET
MET
MET
MET
Thirty-three percent of the samples included in the study had gains of any level in copy number. Of these 22 (3%) tumours had high-level amplification, defined as fulfilling one of the following criteria:/centromere 7 ratio of at least 2.0; average gene copy number per cell of 6.0 or higher; and/or at least 10% of tumour cells containing 15 or more copies of the gene.
Link to the complete article on medwireNews:
